Indoco Remedies Ltd's Q3FY25 Quarter Results
- 1d ago
Result Summary
- Indoco Remedies Ltd reported a 5.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 10.9%.
- Its expenses for the quarter were up by 1.0% QoQ and 2.9% YoY.
- The net profit increased 183.7% QoQ and decreased 282.5% YoY.
- The earnings per share (EPS) of Indoco Remedies Ltd declined at 3.1 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 411.40 | 434.22 | 461.77 | -5.3% | -10.9% |
Total Expenses | 443.35 | 439.06 | 430.94 | 1.0% | 2.9% |
Profit Before Tax | -30.96 | -4.84 | 22.63 | 539.7% | -236.8% |
Tax | -2.56 | 5.17 | 7.07 | -149.5% | -136.2% |
Profit After Tax | -28.40 | -10.01 | 15.56 | 183.7% | -282.5% |
Earnings Per Share | -3.10 | -1.10 | 1.70 | 181.8% | -282.4% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Indoco Remedies Ltd is a pharmaceutical company headquartered in India. The company is primarily engaged in the manufacturing and distribution of pharmaceutical formulations and active pharmaceutical ingredients (APIs). It operates across various therapeutic segments, including respiratory, anti-infectives, gastro-intestinal, cardiovascular, and pain management. Indoco Remedies has a presence in both the domestic and international markets, providing a range of products to cater to the healthcare needs of different regions. As of the latest data available, there are no specific recent major developments mentioned. However, the pharmaceutical industry remains competitive and is characterized by regulatory challenges and innovation-driven growth.
Revenue
During the third quarter of FY25, Indoco Remedies Ltd reported a total income of ₹411.40 crores. This reflects a decline of 5.3% quarter-over-quarter (QoQ) from ₹434.22 crores in the previous quarter (Q2FY25) and a decrease of 10.9% year-over-year (YoY) from ₹461.77 crores in the same quarter last year (Q3FY24). The decline in total income over both quarters and years suggests a contraction in revenue generation for this period. The revenue performance is a critical parameter for the company, indicating its sales and income from operations.
Profitability
In Q3FY25, Indoco Remedies Ltd's profitability metrics show a notable decline. The company reported a loss, with Profit Before Tax (PBT) at -₹30.96 crores, a significant drop from -₹4.84 crores in the previous quarter (Q2FY25) and from a positive ₹22.63 crores in Q3FY24. This marks a substantial change of 539.7% QoQ and a decrease of 236.8% YoY. Consequently, the Profit After Tax (PAT) was -₹28.40 crores, compared to -₹10.01 crores in Q2FY25 and ₹15.56 crores in Q3FY24, indicating a change of 183.7% QoQ and a decline of 282.5% YoY. These figures highlight a significant downturn in profitability over the specified periods, impacting the company's financial health.
Operating Metrics
The company's operating expenses, as reflected in the total expenses, amounted to ₹443.35 crores in Q3FY25, showing an increase of 1.0% QoQ from ₹439.06 crores in Q2FY25 and an increase of 2.9% YoY from ₹430.94 crores in Q3FY24. The Earnings Per Share (EPS) for Q3FY25 was -₹3.10, compared to -₹1.10 in Q2FY25 and ₹1.70 in Q3FY24, indicating a significant downturn both QoQ and YoY by 181.8% and 282.4%, respectively. These metrics illustrate a rise in operational costs alongside a decline in earnings, affecting overall financial performance.
